Immunochromatography test paper and detection pen for detecting respiratory pathogens

CN222014219UActive Publication Date: 2024-11-15ASSURE TECH (HANGZHOU) CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202323622694.6
Authority / Receiving Office
CN · China
Patent Type
Utility models(China)
Current Assignee / Owner
Filing Date
2023-12-28
Publication Date
2024-11-15
Estimated Expiration
2033-12-28

AI Technical Summary

Technical Problem

The existing respiratory virus detection cards cannot achieve multiple joint inspections, and the detection sensitivity is low and the operation is complex, making it difficult to meet the needs of residents and enterprises for cost-saving, easy operation and high-sensitivity detection.

Method used

A detection pen containing three test strips was designed, using the principle of double anti-sandwich method to detect novel coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus, adenovirus, Mycoplasma pneumoniae and Chlamydia pneumoniae, respectively. The readability of the results is enhanced by latex microsphere labeling, and simultaneous detection of 7-8 respiratory pathogens is achieved.

Benefits of technology

Simultaneous detection of 7-8 respiratory pathogens is achieved, which improves the accuracy and accuracy of detection, simplifies operation, reduces costs, and enhances the readability of the results through latex microsphere labeling.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN222014219U_ABST
    Figure CN222014219U_ABST
Patent Text Reader

Abstract

The utility model provides immunochromatography test paper and a detection pen for detecting respiratory tract pathogens, and relates to the technical field of immunochromatography, the immunochromatography test paper comprises a first test strip, a second test strip and a third test strip; each of the first test strip, the second test strip and the third test strip independently comprises a sample pad, a combination pad, a detection pad and a water absorption pad which are sequentially arranged on the bottom plate in the chromatography direction of a sample to be detected; the first test strip is arranged according to the positions of antibodies coated by the combination pad and the detection pad, so that the first test strip is used for detecting novel coronavirus, influenza A virus and influenza B virus; the second test strip is arranged through the positions of antibodies coated by the combination pad and the detection pad, so that the second test strip is used for detecting respiratory syncytial virus, adenovirus and human metapneumovirus; the third test strip is arranged according to the positions of antibodies coated by the combination pad and the detection pad, so that the third test strip is used for detecting the chlamydia pneumoniae and the mycoplasma pneumoniae.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The utility model relates to the technical field of immunochromatographic test papers, in particular to an immunochromatographic test paper and a detection pen for detecting respiratory pathogens. Background Art

[0002] CN212275780U discloses a respiratory virus rapid combined detection card, including a novel coronavirus N protein detection test strip, an influenza A virus detection test strip, an influenza B virus detection test strip and a card case for detecting samples; the card case includes a bottom groove and an upper cover that engage with each other; the novel coronavirus N protein detection test strip, the influenza A virus detection test strip and the influenza B virus detection test strip are respectively arranged on the card case bottom groove. It can be seen that the combined detection card can only achieve the purpose of detecting one respiratory virus with one test strip, but cannot achieve multiple respiratory joint detection.

[0003] CN219201611U discloses a multi-target test strip, on which a sample pad, a binding pad, a reaction membrane and an absorption pad are sequentially formed along the sample flow direction. The binding pad contains antibodies labeled with microspheres of different colors, which bind to antigens corresponding to pathogens. The reaction membrane is sequentially provided with detection lines and quality control lines along the sample flow direction, and the detection lines contain capture antibodies paired with antibodies labeled with microspheres of different colors. The pathogen is selected from one of respiratory pathogens, digestive tract pathogens, Treponema pallidum, and HIV. This product does not set up multiple test strips for specific viruses, but only adopts the method of spraying antibodies of one or more pathogens on a test strip, which will affect the detection sensitivity of the test strip to a certain extent.

[0004] Therefore, both residents and enterprises are in urgent need of a cost-saving, easy-to-operate, and highly sensitive respiratory multi-inspection product. Utility Model Content

[0005] One of the purposes of the utility model is to provide an immunochromatographic test paper for detecting respiratory pathogens, which can simultaneously detect 7 to 8 common respiratory pathogens at one time, and the immunochromatographic test paper has excellent accuracy and precision. At the same time, the corresponding antibodies are labeled with latex microspheres to enhance the readability of the results.

[0006] The second purpose of the utility model is to provide a detection pen, the detection pen includes the immunochromatographic test paper for detecting respiratory pathogens and a shell; the shell includes a base and a pen body. The 7-8 respiratory virus combined detection pen includes three test strips in one pen, and 7-8 items can be detected in one sampling.

[0007] A first aspect. The utility model provides an immunochromatographic test paper for detecting respiratory pathogens, the immunochromatographic test paper comprising a first test strip, a second test strip and a third test strip;

[0008] The first test strip, the second test strip and the third test strip each independently include, along the chromatography direction of the sample to be tested: a sample pad, a binding pad, a detection pad and a water absorption pad sequentially arranged on the bottom plate;

[0009] The conjugate pads are all coated with labeled antibodies labeled with markers;

[0010] Among them, the labeled antibodies coated on the conjugate pad of the first test strip include a first new coronavirus antibody, a first influenza A virus antibody, and a first influenza B virus antibody; the labeled antibodies coated on the conjugate pad of the second test strip include a first respiratory syncytial virus antibody and a first adenovirus antibody; the labeled antibodies coated on the conjugate pad of the third test strip include a first Mycoplasma pneumoniae antibody and a first Chlamydia pneumoniae antibody;

[0011] The detection pads are all coated with detection antibodies;

[0012] Among them, the detection antibodies coated on the detection pad of the first test strip include a second new coronavirus antibody, a second influenza A virus antibody and a second influenza B virus antibody; the detection antibodies coated on the detection pad of the second test strip include a second respiratory syncytial virus antibody and a second adenovirus antibody; the detection antibodies coated on the detection pad of the third test strip include a second Mycoplasma pneumoniae antibody and a second Chlamydia pneumoniae antibody.

[0013] It should be noted that the utility model adopts the principle of double antibody sandwich method, and the detection antibody and the corresponding labeled antibody simultaneously bind to the same antigen to form a first antibody-antigen-second antibody complex, thereby realizing the detection of pathogens.

[0014] More specifically, in the implementation of the present invention, the first influenza A virus antibody and the second influenza A virus antibody can simultaneously bind to the influenza A virus antigen; the first influenza B virus antibody and the second influenza B virus antibody can simultaneously bind to the influenza B virus antigen; the first new coronavirus antibody and the second new coronavirus antibody can simultaneously bind to the new coronavirus antigen; the first human respiratory syncytial virus antibody and the second human respiratory syncytial virus antibody can simultaneously bind to the respiratory syncytial virus; the first adenovirus antibody and the second adenovirus antibody can simultaneously bind to the adenovirus antigen; the first Chlamydia pneumoniae antibody and the second Chlamydia pneumoniae antibody can simultaneously bind to the Chlamydia pneumoniae antigen; the first Mycoplasma pneumoniae antibody and the second Mycoplasma pneumoniae antibody can simultaneously bind to the Mycoplasma pneumoniae antigen.

[0015] In addition, the detection antibody and its corresponding labeled antibody can be the same or different. If the same antibody can bind to the same antigen at the same time, for example, bind to repeated antigen epitopes at different positions of the same antigen, then the same antibody can be used as the labeled antibody and the detection antibody at the same time.

[0016] In some optional embodiments, the first influenza A virus antibody and the second influenza A virus antibody optionally recognize any antigen of influenza A virus, and the recognized antigen may be a natural antigen or a recombinant antigen; in some optional embodiments, the first influenza A virus antibody and the second influenza A virus antibody recognize influenza A virus N protein (nucleocapsid protein), which may be a recombinant N protein.

[0017] In some optional embodiments, the first influenza B virus antibody and the second influenza B virus antibody optionally recognize any antigen of influenza B virus, and the recognized antigen can be a natural antigen or a recombinant antigen. In some optional embodiments, the first influenza B virus antibody and the second influenza B virus antibody recognize influenza B virus N protein, which can be a recombinant N protein.

[0018] In some optional embodiments, the first novel coronavirus antibody and the second novel coronavirus antibody optionally recognize any antigen of the novel coronavirus, and the recognized antigen can be a natural antigen or a recombinant antigen. In some optional embodiments, the first novel coronavirus antibody and the second novel coronavirus antibody recognize the novel coronavirus N protein, which can be a recombinant N protein.

[0019] In some optional embodiments, the first human metapneumovirus antibody and the second human metapneumovirus antibody optionally recognize any antigen of human metapneumovirus, and the recognized antigen can be a natural antigen or a recombinant antigen. In some optional embodiments, the first human metapneumovirus antibody and the second human metapneumovirus antibody recognize a recombinant protein of human metapneumovirus, optionally a recombinant M protein.

[0020] In some optional embodiments, the first respiratory syncytial virus antibody and the second respiratory syncytial virus antibody optionally recognize any antigen of the respiratory syncytial virus, and the recognized antigen can be a natural antigen or a recombinant antigen. In some optional embodiments, the first respiratory syncytial virus antibody and the second respiratory syncytial virus antibody recognize the respiratory syncytial virus N protein, which is optionally a recombinant N protein.

[0021] In some optional embodiments, the first adenovirus antibody and the second adenovirus antibody optionally recognize any antigen of adenovirus, and the recognized antigen can be a natural antigen or a recombinant antigen. In some optional embodiments, the first adenovirus antibody and the second adenovirus antibody recognize adenovirus Hexon protein, which can be a recombinant Hexon protein.

[0022] In some optional embodiments, the first Chlamydia pneumoniae antibody and the second Chlamydia pneumoniae antibody optionally recognize any antigen of Chlamydia pneumoniae, and the recognized antigen can be a natural antigen or a recombinant antigen. In some optional embodiments, the first Chlamydia pneumoniae antibody and the second Chlamydia pneumoniae antibody recognize a Chlamydia pneumoniae-specific antigen, which can be a recombinant antigen.

[0023] In some optional embodiments, the first Mycoplasma pneumoniae antibody and the second Mycoplasma pneumoniae antibody optionally recognize any antigen of Mycoplasma pneumoniae, and the recognized antigen may be a natural antigen or a recombinant antigen. In some optional embodiments, the first Mycoplasma pneumoniae antibody and the second Mycoplasma pneumoniae antibody recognize a Mycoplasma pneumoniae-specific antigen, which may be a recombinant antigen.

[0024] In the present invention, the labeled antibody coated on the binding pad of the second test strip also includes a first human metapneumovirus antibody; and the detection antibody coated on the detection pad of the second test strip also includes a second human metapneumovirus antibody.

[0025] As described above, the utility model adopts the principle of double antibody sandwich method, wherein the detection antibody and the corresponding labeled antibody simultaneously bind to the same antigen to form a first antibody-antigen-second antibody complex, thereby realizing the detection of pathogens. More specifically, the first human metapneumovirus antibody and the second human metapneumovirus antibody can simultaneously bind to the human metapneumovirus antigen.

[0026] In some alternative embodiments, the first human metapneumovirus antibody and the second human metapneumovirus antibody recognize a human metapneumovirus protein, optionally a recombinant protein.

[0027] In the present invention, the conjugate pad of the first test strip is composed of a single conjugate pad or 2 to 3 overlapping conjugate pads.

[0028] In some optional embodiments, the conjugate pad design scheme I of the first test strip is: the conjugate pad of the first test strip is composed of a single conjugate pad, and the labeled antibody coated on the conjugate pad is a combination of a first new coronavirus antibody, a first influenza A virus antibody and a first influenza B virus antibody.

[0029] In some optional embodiments, the conjugate pad design scheme II of the first test strip: the conjugate pad of the first test strip includes: a second conjugate pad and a first conjugate pad along the chromatography direction of the sample to be tested; when the first conjugate pad is coated with the first influenza A virus antibody and the first influenza B virus antibody, the second conjugate pad is coated with the first new coronavirus antibody; when the first conjugate pad is coated with the first new coronavirus antibody, the second conjugate pad is coated with the first influenza A virus antibody and the first influenza B virus antibody;

[0030] In some optional embodiments, the conjugate pad design scheme III of the first test strip: the conjugate pad of the first test strip includes: a third conjugate pad, a second conjugate pad and a first conjugate pad along the chromatography direction of the sample to be tested; the first conjugate pad is coated with a first influenza A virus antibody, the second conjugate pad is coated with a first influenza B virus antibody, and the third conjugate pad is coated with a first new coronavirus antibody.

[0031] In the present invention, the conjugate pad of the second test strip is composed of a single conjugate pad or two overlapping conjugate pads.

[0032] In some optional embodiments, the conjugate pad design scheme I of the second test strip: the conjugate pad of the second test strip is composed of a single conjugate pad, and the labeled antibodies coated on the conjugate pad are a first respiratory syncytial virus antibody and a first adenovirus antibody; and / or, the labeled antibodies coated on the conjugate pad also include a first human metapneumovirus antibody.

[0033] In some optional embodiments, the conjugate pad design scheme II of the second test strip: the conjugate pad of the second test strip includes: a second conjugate pad and a first conjugate pad along the chromatography direction of the sample to be tested; when the first conjugate pad is coated with the first respiratory syncytial virus antibody and the first adenovirus antibody, the second conjugate pad is coated with the first human metapneumovirus antibody; when the first conjugate pad is coated with the first human metapneumovirus antibody, the second conjugate pad is coated with the first respiratory syncytial virus antibody and the first adenovirus antibody.

[0034] In the present invention, the conjugate pad of the third test strip is composed of a single conjugate pad; the labeled antibody coated on the conjugate pad of the third test strip is a combination of a first Mycoplasma pneumoniae antibody and a first Chlamydia pneumoniae antibody.

[0035] In some optional embodiments, the detection pad (COV&FLUA&FLUB detection pad) of the first test strip includes: detection line T3, detection line T2, detection line T1 and quality control line C along the chromatography direction of the sample to be tested; wherein, the second new coronavirus antibody is coated in the area of ​​detection line T3, the second influenza A virus antibody is coated in the area of ​​detection line T2, and the second influenza B virus antibody is coated in the area of ​​detection line T1.

[0036] In some optional embodiments, the detection pad (RSV&ADV detection pad) of the second test strip includes: a detection line T2, a detection line T1 and a quality control line C along the chromatography direction of the sample to be tested; wherein the second adenovirus antibody is coated in the area of ​​the detection line T1, and the second respiratory syncytial virus antibody is coated in the area of ​​the detection line T2.

[0037] In some optional embodiments, the detection pad (RSV&ADV&HMPV detection pad) of the second test strip includes: detection line T3, detection line T2, detection line T1 and quality control line C along the chromatography direction of the sample to be tested; wherein, the second human metapneumovirus antibody 2 is coated in the area of ​​the detection line T3, the second respiratory syncytial virus antibody 2 is coated in the area of ​​the detection line T2, and the second adenovirus antibody is coated in the area of ​​the detection line T1.

[0038] In some optional embodiments, the detection pad (MP&CP detection pad) of the third test strip includes: a detection line T2, a detection line T1 and a quality control line C along the chromatography direction of the sample to be tested; wherein the second Chlamydia pneumoniae antibody is coated in the area of ​​the detection line T2, and the second Mycoplasma pneumoniae antibody is coated in the area of ​​the detection line T1.

[0039] In the present invention, the materials constituting the various parts of the immunochromatographic test paper (such as the sample pad, the conjugate pad, the detection pad and the absorbent pad, etc.) can be selected from acceptable and well-known materials in the art.

[0040] In some optional embodiments, the sample pad is selected from any one of glass fiber membrane, polyester fiber membrane or non-woven fabric, preferably glass fiber membrane.

[0041] In some optional embodiments, the binding pad is selected from any one of glass fiber membrane, polyester fiber membrane or non-woven fabric, preferably polyester fiber membrane.

[0042] In some optional embodiments, the detection pad is selected from nitrocellulose membrane.

[0043] In some optional embodiments, the absorbent pad is selected from absorbent paper.

[0044] In some optional embodiments, the detection pad may optionally overlap with the binding pad by 1 to 3 mm, for example, 1 mm, 1.2 mm, 1.4 mm, 1.6 mm, 1.8 mm, 2 mm, 2.2 mm, 2.4 mm, 2.6 mm, 2.8 mm, 3 mm, etc.

[0045] In some optional embodiments, the conjugate pad optionally overlaps with the sample pad by 1 to 3 mm, for example, 1 mm, 1.2 mm, 1.4 mm, 1.6 mm, 1.8 mm, 2 mm, 2.2 mm, 2.4 mm, 2.6 mm, 2.8 mm, 3 mm, etc.

[0046] In some optional embodiments, the absorbent pad is located on a fixed bottom plate, and the detection pad, conjugate pad and sample pad are arranged in sequence, with each part overlapping by 1 to 3 mm, for example, it can be 1 mm, 1.2 mm, 1.4 mm, 1.6 mm, 1.8 mm, 2 mm, 2.2 mm, 2.4 mm, 2.6 mm, 2.8 mm, 3 mm, etc.

[0047] In some optional embodiments, the label is a colored latex particle (the label refers to the label coated on the conjugate pad for the primary antibody).

[0048] In some optional embodiments, the mass ratio of the first novel coronavirus antibody, the first influenza A virus antibody, the first influenza B virus antibody, the first respiratory syncytial virus antibody, the first adenovirus antibody, the first human metapneumovirus antibody, the first Mycoplasma pneumoniae antibody, and the first Chlamydia pneumoniae antibody to the colored latex particles in the conjugate pad coating solution is 1:(20-80), for example, it can be 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, etc.

[0049] In some optional embodiments, the particle size of the colored latex particles is 200-400 nm, for example, 200 nm, 250 nm, 300 nm, 350 nm, 400 nm, etc.

[0050] In some optional embodiments, the quality control line C is coated with a mixed solution of reactive blue powder and colored latex microspheres labeled with bovine serum albumin (BSA).

[0051] In some optional embodiments, the colored latex includes any one of red, blue or green latex, preferably green latex particles.

[0052] In some optional embodiments, the spray volume of the coating liquid on the detection line of the detection pad of the first test strip is 0.7-1.3 μL / cm, for example, it can be 0.7 μL / cm, 0.8 μL / cm, 0.9 μL / cm, 1.0 μL / cm, 1.1 μL / cm, 1.2 μL / cm, 1.3 μL / cm, etc., and more preferably 0.9 μL / cm.

[0053] In some optional embodiments, the spray volume of the coating liquid on the detection line of the detection pad of the second test strip is 0.7-1.3 μL / cm, for example, it can be 0.7 μL / cm, 0.8 μL / cm, 0.9 μL / cm, 1.0 μL / cm, 1.1 μL / cm, 1.2 μL / cm, 1.3 μL / cm, etc., and more preferably 0.9 μL / cm.

[0054] In some optional embodiments, the spray volume of the coating liquid on the detection line of the detection pad of the third test strip is 0.7-1.3 μL / cm, for example, it can be 0.7 μL / cm, 0.8 μL / cm, 0.9 μL / cm, 1.0 μL / cm, 1.1 μL / cm, 1.2 μL / cm, 1.3 μL / cm, etc., and more preferably 0.9 μL / cm.

[0055] In a second aspect, the utility model provides a detection pen, which includes the immunochromatographic test paper for detecting respiratory pathogens as described in the first aspect and a shell; the shell includes a base and a pen body.

[0056] In some optional embodiments, the base is filled with a sample lysis solution;

[0057] The pen body is provided with a card slot for fixing the immunochromatographic test paper for detecting respiratory pathogens, and one end of the pen body close to the sample pad is provided with a sampling part in contact with the sample pad; the base is provided with a buckle for fixing the pen body; after the pen body is inserted into the base, the sampling part contacts the sample lysis solution, and the pen body is provided with a visual part for observing the detection pad.

[0058] The above-mentioned shell includes a base and a pen body. The base is pre-installed with sample lysis solution, and a slot for fixing the immunochromatographic test paper is provided in the pen body, and a sampling part in contact with the sample pad is provided at one end of the pen body close to the sample pad, and the sampling part is a sponge sampling head; the base is provided with a buckle for fixing the pen body; after the pen body is inserted into the base, the sampling part contacts the sample lysis solution. The immunochromatographic test paper is pre-installed in the shell, and after fixation, the sample pad of the immunochromatographic test paper contacts the sampling part of the pen body. After sampling, the pen body is inserted into the base and fixed by the buckle, and the sponge sampling head contacts the sample lysis solution. Through the upward chromatography effect, the immunochromatographic test paper in the pen body detects the sample to be tested.

[0059] In a third aspect, the utility model provides a method for using a virus combined detection pen, the method comprising the following steps:

[0060] The sample to be tested is added to the sample pad of the immunochromatographic test paper described in the first aspect at one time, or the sample is directly taken using the detection pen described in the second aspect, and the color of the detection line and the quality control line on the chromatographic test paper is observed to obtain the test result.

[0061] Furthermore, the detection method comprises the following steps:

[0062] S1. Collect samples:

[0063] Use the sampling tip in the test pen to take samples from the patient's nasal mucosa; or, use a pipette to apply a quality control product of a specific concentration to the sampling tip of the test pen;

[0064] S2. Test samples:

[0065] Insert the sample head into the base containing the sample lysis solution, let it stand for a while and then perform chromatography; observe the output line for a period of time;

[0066] S3. Interpretation of results:

[0067] The C-line quality control zone detection line is set to navy blue and turns green after chromatography, indicating that the result is valid.

[0068] In order to improve the appearance and readability of the results, the test strip 1 is designed with different colors:

[0069] First test strip: 3 T lines are set to red or blue; the detection line T1 of the first test strip is red when FluB is present, the detection line T2 is blue when FluA is present, and the detection line T3 is red when COV is present;

[0070] Second test strip: 3 T lines are set to red; the detection line T1 of the second test strip is red when ADV is out, the detection line T2 is red when RSV is out, and the detection line T3 is red when HMPV is out;

[0071] The third test strip: the two T lines are set to red; the detection line T1 of the third test strip appears red when the MP line is out, and the detection line T2 appears red when the CP line is out.

[0072] Compared with the prior art, the utility model has the following beneficial effects:

[0073] (1) The immunochromatographic test paper of the utility model can detect 7 to 8 common respiratory pathogens at the same time, and detect them at one time. The respiratory viruses include: new coronavirus, influenza A virus, influenza B virus, human metapneumovirus, respiratory syncytial virus, adenovirus, Mycoplasma pneumoniae, Chlamydia pneumoniae, and only one sample needs to be added, which is easy to operate and saves costs. This idea is used to detect antigens or antibodies of the same sample type.

[0074] (2) The immunochromatographic test paper of the utility model has excellent accuracy and precision. At the same time, the corresponding antibodies are labeled with latex microspheres, which enhances the readability of the results. BRIEF DESCRIPTION OF THE DRAWINGS

[0075] In order to more clearly illustrate the specific implementation methods of the utility model or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the utility model. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0076] Figure 1 A schematic structural diagram of a first test strip in an immunochromatographic test strip for detecting respiratory pathogens provided in an embodiment of the utility model.

[0077] Among them, 1 is a water-absorbing pad; 2 is a quality control line C; 3 is an influenza B virus detection line T1; 4 is an influenza A virus detection line T2; 5 is a new coronavirus detection line T3; 6 is a first binding pad; 7 is a second binding pad; 8 is a sample pad; 9 is a detection pad; and 10 is a bottom plate.

[0078] Figure 2 A schematic diagram of the structure of a second test strip in an immunochromatographic test strip for detecting respiratory pathogens provided in an embodiment of the utility model.

[0079] Among them, 1 is a water-absorbing pad; 2 is a quality control line C; 3 is an adenovirus detection line T1; 4 is a respiratory syncytial virus detection line T2; 5 is a human metapneumovirus detection line T3; 6 is a first binding pad; 7 is a second binding pad; 8 is a sample pad; 9 is a detection pad; and 10 is a bottom plate.

[0080] Figure 3 This is a schematic structural diagram of the third test strip in the immunochromatographic test strip for detecting respiratory pathogens provided in an embodiment of the utility model.

[0081] Among them, 1 is the absorbent pad; 2 is the quality control line C; 3 is the Mycoplasma pneumoniae detection line T1; 4 is the Chlamydia pneumoniae detection line T2; 5 is the binding pad; 6 is the sample pad; 7 is the detection pad; and 8 is the bottom plate.

[0082] Figure 4 A schematic diagram of interpreting the test results of the first test strip in the immunochromatographic test paper for detecting respiratory pathogens provided in an embodiment of the utility model.

[0083] Figure 5 A schematic diagram of interpreting the test results of the second test strip in the immunochromatographic test paper for detecting respiratory pathogens provided in an embodiment of the utility model.

[0084] Figure 6 A schematic diagram of interpreting the test results of the third test strip in the immunochromatographic test paper for detecting respiratory pathogens provided in an embodiment of the utility model. DETAILED DESCRIPTION

[0085] The technical solution of the utility model will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the utility model, not all of the embodiments. Based on the embodiments of the utility model, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the utility model.

[0086] It should be noted that in this article, "new coronavirus", "COVID-19", "COV" and "COV" all refer to the new coronavirus and can be used interchangeably; in this article, "influenza A virus", "influenza A virus", "flu", "FLUA" and "FluA" all refer to influenza A virus and can be used interchangeably; in this article, "influenza B virus", "influenza B virus", "flu", "FLUB" and "FluB" all refer to influenza B virus and can be used interchangeably; in this article, "respiratory syncytial virus", "syncytial virus" and "RSV" all refer to respiratory syncytial virus and can be used interchangeably; in this article, "adenovirus" and "ADV" all refer to adenovirus and can be used interchangeably; in this article, "human metapneumovirus" and "HMPV" all refer to human metapneumovirus and can be used interchangeably; in this article, "Chlamydia pneumoniae", "Chlamydia" and "CP" all refer to Chlamydia pneumoniae and can be used interchangeably; in this article, "Mycoplasma pneumoniae", "Mycoplasma" and "MP" all refer to Mycoplasma pneumoniae and can be used interchangeably.

[0087] It should be noted that, in this article, "coating", "embedding" and "spraying" all refer to fixing antibodies on immunochromatographic test paper and can be used interchangeably.

[0088] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features.

[0089] The present invention is further described below by way of examples. Unless otherwise specified, the materials in the examples are prepared according to existing methods or purchased directly from the market.

[0090] ① The sources of viral antibodies in the following examples are as follows:

[0091] The first influenza A virus antibody was from Hangzhou Xuke Biotechnology, with the product number R1403 (marker);

[0092] The second influenza A virus antibody was from Hangzhou Xuke Biotechnology, with the product number R1401 (coated);

[0093] The first influenza B virus antibody was from Hangzhou Xuke Biotechnology, with the product number R1404 (marker);

[0094] The second influenza B virus antibody was from Hangzhou Xuke Biotechnology, with the product number R1402 (coated);

[0095] The first novel coronavirus antibody comes from Hangzhou Xuke Biotechnology, with the product number RM0032 (marker);

[0096] The second novel coronavirus antibody comes from Hangzhou Xuke Biotechnology, with the product number RM0033 (encapsulated);

[0097] The first respiratory syncytial virus antibody was from Hangzhou Xuke Biotechnology, with the product number R4005 (marker);

[0098] The second respiratory syncytial virus antibody was from Hangzhou Xuke Biotechnology, with the product number R4006 (coated);

[0099] The first adenovirus antibody was from Hangzhou Xuke Biotechnology, with the catalog number R4003 (marker);

[0100] The second adenovirus antibody was from Hangzhou Xuke Biotechnology, with the catalog number R4004 (encapsulated);

[0101] The first human metapneumovirus antibody came from Hangzhou Xuke Biotechnology, with the catalog number RM0102 (marker);

[0102] The second human metapneumovirus antibody was from Hangzhou Xuke Biotechnology, with the catalog number RM0103 (encapsulated);

[0103] The first Mycoplasma pneumoniae antibody was from Hangzhou Xuke Biotechnology, with the catalog number RD0011 (marker);

[0104] The second Mycoplasma pneumoniae antibody was from Hangzhou Xuke Biotechnology, with the catalog number RD0012 (encapsulated);

[0105] The first Chlamydia pneumoniae antibody was from Hangzhou Xuke Biotechnology, with the catalog number RD0083 (marker);

[0106] The second Chlamydia pneumoniae antibody comes from Hangzhou Xuke Biotechnology, with the product number RD0084 (coated).

[0107] ②The quality control information used below is as follows:

[0108] The recombinant nucleocapsid protein of the new coronavirus comes from Hangzhou Xuke Biological, with the product number R1320;

[0109] Influenza B nucleocapsid protein was from Hangzhou Xuke Biological, catalog number R1301;

[0110] Influenza A nucleocapsid protein was from Hangzhou Xuke Biotechnology with the catalog number Q0015;

[0111] Adenovirus natural antigens were from the Adenoid6 strain of Microbix;

[0112] Respiratory syncytial virus natural antigen is from AoChuang Biotechnology, product number is C146-P1;

[0113] Human metapneumovirus antigen is a recombinant protein from Hangzhou Xuke Biotechnology, with the product number RM0104;

[0114] Mycoplasma pneumoniae quality control was from Hangzhou Xuke Biological, with the catalog number M1010;

[0115] The quality control of Chlamydia pneumoniae comes from Hangzhou Xuke Biological, with the product number C4011.

[0116] ③ The sample collection and detection process of the following embodiments are as follows:

[0117] The immunochromatographic test papers provided in the following embodiments are installed in a pen-shaped housing: a detection pen, the housing includes a base and a pen body.

[0118] The base is pre-installed with sample lysis solution, a card slot for fixing the immunochromatographic test paper is arranged in the pen body, and a sampling part in contact with the sample pad is arranged at one end of the pen body close to the sample pad, and the sampling part is a sponge sampling head; the base is provided with a buckle for fixing the pen body; after the pen body is inserted into the base, the sampling part contacts with the sample lysis solution.

[0119] The immunochromatographic test paper provided in each embodiment is pre-installed in a shell. After fixation, the sample pad of the immunochromatographic test paper contacts the sampling part of the pen body. After sampling, the pen body is inserted into the base and fixed by a snap. The sponge sampling head contacts the sample lysate. Through the upward chromatography effect, the immunochromatographic test paper in the pen body detects the sample to be tested.

[0120] S1. Collect samples:

[0121] The sample type is a human nasal swab, and the collection method includes the following steps:

[0122] (1) Insert the sponge sampling tip of the test pen into the nasal cavity 2 to 3 cm away, and scrape the sponge tip clockwise inside the nasal cavity for 5 circles, close to the nasal mucosa. After scraping, remove it and perform the same operation in the other nasal cavity. When sampling, appropriate force should be applied to ensure that the sample is taken from the human nasal mucosa;

[0123] (2) When performing drug validation or serum sampling in the laboratory, use a pipette to evenly apply 50 μL of serum sample onto the sponge sampling head;

[0124] (3) When taking samples in batches, put the plastic cap on the sponge head after sampling, put it into the sample bag, seal it and mark it.

[0125] S2. Test samples:

[0126] (1) When screening for suspected infectious sources, testers must wear protective clothing, medical masks, medical surgical gloves and other protective equipment in accordance with the protective measures for infectious diseases. Small-scale on-site direct sampling and testing such as self-testing by residents is sufficient;

[0127] (2) Insert the sampled sampling head into the base containing the sample lysis solution and let it stand for 15 minutes for chromatography. The base should be placed vertically on the desktop. When inserting the sampling head into the base containing the sample lysis solution, a "click" sound should be heard. During chromatography, the base and the detection pen should be perpendicular to the desktop or the detection table for upward chromatography. Try to avoid shaking the pen body and the base or perpendicular to the detection table. Observe whether the sample is chromatographed normally;

[0128] (3) After 15 minutes, observe the output line. After the test, the used test pen and base shall be disposed of as biomedical waste.

[0129] S3. Interpretation of results:

[0130] In the following test examples, three or more parallel samples are used for testing, and the results are the color values ​​or average values ​​of more than 95% of the parallel samples. The color values ​​of the test line and the quality control line are referenced from the colorimetric card, which is printed with color blocks with color development from light to dark. The color development of the color blocks is measured and calibrated for reflectance every year according to the national metrology technical specification JJF1232-2009. The color value range of the color card is 1-10, and the higher the number, the darker the color. Among them, the chromaticity reading of 3.5 and above is judged as a line visible to the naked eye. The depth of the T line in the subsequent tables is expressed in this reading. Therefore, the criterion for judging whether the line is visible to the naked eye is whether the color chromaticity of the T line reaches the color card reading of 3.5, where "-" indicates negative.

[0131] The C-line quality control zone detection line is set to navy blue and turns green after chromatography, indicating that the result is valid.

[0132] In order to improve the appearance and readability of the results, the test strip 1 is designed with different colors:

[0133] First test strip: 3 T lines are set to red or blue; the detection line T1 of the first test strip is red when FluB is present, the detection line T2 is blue when FluA is present, and the detection line T3 is red when COV is present;

[0134] Second test strip: 3 T lines are set to red; the detection line T1 of the second test strip is red when ADV is out, the detection line T2 is red when RSV is out, and the detection line T3 is red when HMPV is out;

[0135] The third test strip: the two T lines are set to red; the detection line T1 of the third test strip appears red when the MP line is out, and the detection line T2 appears red when the CP line is out.

[0136] The test result of the first test strip is as follows Figure 4As shown: A infected with influenza B, B infected with influenza A and influenza B, C infected with influenza B and COVID-19, D infected with both influenza A, influenza B and COVID-19, E infected with influenza A and COVID-19, F infected with COVID-19, G infected with influenza A, H negative IX result is invalid.

[0137] The test result of the second test strip is as follows Figure 5 As shown: A infected with adenovirus, B infected with adenovirus, respiratory syncytial virus, C infected with adenovirus, human metapneumovirus, D infected with respiratory syncytial virus, adenovirus, human metapneumovirus, E infected with respiratory syncytial virus, human metapneumovirus, F infected with human metapneumovirus, G infected with respiratory syncytial virus, H negative, IW result is invalid.

[0138] The test results of the third test strip are as follows Figure 6 Shown: A infected with Mycoplasma pneumoniae, B infected with Mycoplasma pneumoniae and Chlamydia pneumoniae, C infected with Chlamydia pneumoniae, D negative, EH result is invalid.

[0139] Example 1

[0140] This embodiment provides an immunochromatographic test paper for detecting respiratory pathogens, wherein the immunochromatographic test paper comprises a first test strip, a second test strip, and a third test strip.

[0141] like Figure 1 As shown, the first test strip independently includes: a sample pad 8, a second conjugation pad 7, a first conjugation pad 6, a detection pad 9 and a water absorption pad 1 which are sequentially arranged on a bottom plate 10 along the chromatography direction (Flow direction) of the sample to be tested.

[0142] The detection pad (COV&FLUA&FLUB detection pad) of the first test strip includes: detection line T3, detection line T2, detection line T1 and quality control line C along the chromatography direction of the sample to be tested; wherein, the second new coronavirus (COV) antibody is coated in the area of ​​the detection line T3, the second influenza A virus (FluA) antibody is coated in the area of ​​the detection line T2, and the second influenza B virus (FluB) antibody is coated in the area of ​​the detection line T1.

[0143] The conjugate pad (COV&FLUA&FLUB conjugate pad) of the first test strip includes: a second conjugate pad 7 and a first conjugate pad 6 along the chromatography direction of the sample to be tested; wherein the first conjugate pad is coated with a first influenza A virus (FluA) antibody and a first influenza B virus (FluB) antibody, and the second conjugate pad is coated with a first new coronavirus (COV) antibody.

[0144] like Figure 2 As shown, the second test strip independently includes: a sample pad 8, a second conjugation pad 7, a first conjugation pad 6, a detection pad 9 and a water absorption pad 1 which are sequentially arranged on a bottom plate 10 along the chromatography direction (Flow direction) of the sample to be tested.

[0145] The detection pad (RSV&ADV&HMPV detection pad) of the second test strip includes: detection line T3, detection line T2, detection line T1 and quality control line C along the chromatography direction of the sample to be tested; wherein, the second human metapneumovirus (HMPV) antibody is coated in the area of ​​the detection line T3, the second respiratory syncytial virus (RSV) antibody is coated in the area of ​​the detection line T2, and the second adenovirus (ADV) antibody is coated in the area of ​​the detection line T1.

[0146] The conjugate pad (RSV&ADV&HMPV conjugate pad) of the second test strip includes: a second conjugate pad 7 and a first conjugate pad 6 along the chromatography direction of the sample to be tested; wherein the first conjugate pad is coated with a first respiratory syncytial virus (RSV) antibody and a first adenovirus (ADV) antibody, and the second conjugate pad is coated with a first human metapneumovirus (HMPV) antibody.

[0147] like Figure 3 As shown, the third test strip independently includes: a sample pad 6, a binding pad 5, a detection pad 6 and a water absorption pad 1 which are sequentially arranged on the bottom plate 10 along the chromatography direction (Flow direction) of the sample to be tested.

[0148] The detection pad (MP&CP detection pad) of the third test strip includes: a detection line T2, a detection line T1 and a quality control line C along the chromatography direction of the sample to be tested; wherein the second Chlamydia pneumoniae (CP) antibody is coated in the area of ​​the detection line T2, and the second Mycoplasma pneumoniae (MP) antibody is coated in the area of ​​the detection line T1.

[0149] The conjugate pad (MP&CP conjugate pad) of the third test strip includes, along the chromatography direction of the sample to be tested: a conjugate pad 6; wherein the conjugate pad is coated with a first Chlamydia pneumoniae (CP) antibody and a second Mycoplasma pneumoniae (MP) antibody.

[0150] The sample pad 8 is a glass fiber membrane, the second conjugation pad 7 is a polyester fiber membrane, the first conjugation pad 6 is a polyester fiber membrane, the detection pad 9 is a nitrocellulose membrane, and the absorbent pad 1 is absorbent paper.

[0151] Comparative Examples 1 to 6

[0152] Comparative Examples 1 to 6 provide different combinations of immunochromatographic test strips for detecting respiratory pathogens. The only difference from Example 1 is that the first test strip, the second test strip, and the third test strip detect different viruses. It should be noted that the types of antibodies on the detection pad and the detection line are adjusted accordingly according to the following Table 1.

[0153] Table 1

[0154] sample First test strip Second test strip The third test strip Comparative Example 1 COV+FluA FluB+RSV+ADV MP+CP+HMPV Comparative Example 2 FluA+FluB RSV+ADV+HMPV COV+MP+CP Comparative Example 3 COV+FluA+FluB MP+HMPV CP+ADV+RSV Comparative Example 4 FluA+FluB+HMPV RSV+COV ADV+MP+CP Comparative Example 5 FluA+FluB+RSV ADV+COV+HMPV MP+CP Comparative Example 6 FluA+FluB+ADV COV+HMPV MP+CP+RSV

[0155] Test Example 1

[0156] Optimization of virus combination arrangement on test strips

[0157] Test sample: immunochromatographic test paper provided in Example 1 and Comparative Examples 1 to 6;

[0158] The test results are shown in Table 2 below:

[0159] Table 2

[0160]

[0161]

[0162] As shown in Table 2, when the labeled antibodies coated on the conjugate pad of the first test strip include a first novel coronavirus antibody, a first influenza A virus antibody, and a first influenza B virus antibody; the labeled antibodies coated on the conjugate pad of the second test strip include a first respiratory syncytial virus antibody and a first adenovirus antibody; the labeled antibodies coated on the conjugate pad of the third test strip include a first Mycoplasma pneumoniae antibody and a first Chlamydia pneumoniae antibody; the detection antibodies coated on the detection pad of the first test strip include a second novel coronavirus antibody, a second influenza A virus antibody, and a second influenza B virus antibody; the detection antibodies coated on the detection pad of the second test strip include a second respiratory syncytial virus antibody and a second adenovirus antibody; and the detection antibodies coated on the detection pad of the third test strip include a second Mycoplasma pneumoniae antibody and a second Chlamydia pneumoniae antibody, the reading result on the membrane surface is optimal and the sensitivity is highest.

[0163] Embodiments 2 to 12

[0164] Among them, Examples 2 to 6 provide different immunochromatographic test strips for detecting respiratory pathogens, which differ from Example 1 only in that the position sequence of the T lines of the first test strip is different, as shown in Table 3 below;

[0165] Table 3

[0166]

[0167]

[0168] Among them, Examples 7 to 11 provide different immunochromatographic test strips for detecting respiratory pathogens, which differ from Example 1 only in that the position sequence of the T lines of the second test strip is different, as shown in Table 4 below;

[0169] Table 4

[0170] Experimental Group T1 T2 T3 Example 1 ADV RSV HMPV Example 7 RSV HMPV ADV Example 8 RSV ADV HMPV Example 9 ADV HMPV RSV Example 10 HMPV RSV ADV Embodiment 11 HMPV ADV RSV

[0171] Among them, Example 12 provides a different immunochromatographic test strip for detecting respiratory pathogens, which differs from Example 1 only in that the position sequence of the T lines of the third test strip is different, as shown in Table 7 below;

[0172] Table 5

[0173] Experimental Group T1 T2 Example 1 ADV RSV Example 12 RSV HMPV

[0174] Test Example 2

[0175] T-line position order optimization

[0176] Test sample: immunochromatographic test paper provided in Examples 1 to 12;

[0177] The positive quality control concentration used in this test example is 2 times the LOD of a single product. The test results are shown in Tables 6 to 8 below:

[0178] Table 6

[0179]

[0180] As shown in the above table, Example 1 has the highest sensitivity, so the T lines of the test strip 1 are arranged in the order of T1: FluB; T2: FluA; T3: COV.

[0181] Table 7

[0182]

[0183] As shown in the above table, Example 1 has the highest sensitivity, so the T lines of test strip 2 are arranged in the order of T1: ADV; T2: RSV; T3: HMPV.

[0184] Table 8

[0185] Experimental Group T1 line reading T2 line reading Example 1 5 (MP) 5(CP) Example 12 5(CP) 4 (MP)

[0186] As shown in the above table, Example 1 has the highest sensitivity, so the T lines of the test strip 3 are arranged in the order of T1: MP; T2: CP.

[0187] Embodiments 13 to 15

[0188] Among them, Examples 13 to 15 provide different immunochromatographic test strips for detecting respiratory pathogens, which differ from Example 1 only in that the number of detection pads on the first test strip is different, as shown in Table 9 below;

[0189] Table 9

[0190] Experimental Group Number of bonding pads Bonding pad 1 Bonding pad 2 Bonding pad 3 Example 1 2 (FluA+FluB)latex COV Latex / Example 13 3 FluA latex FluB Latex COV Latex Embodiment 14 2 COV Latex (FluA+FluB)latex / Embodiment 15 1 (FluA+FluB+COV)latex / /

[0191] Among them, Example 16 provides a different immunochromatographic test strip for detecting respiratory pathogens, which differs from Example 1 only in that the number of detection pads on the second test strip is different, as shown in Table 10 below;

[0192] Table 10

[0193] Experimental Group Number of bonding pads Bonding pad 1 Bonding pad 2 Example 1 2 RSV+ADV Latex HMPV Latex Example 16 1 (RSV+ADV+HMPV)latex /

[0194] Among them, Example 17 provides different immunochromatographic test strips for detecting respiratory pathogens, which differ from Example 1 only in that the number of detection pads on the third test strip is different, as shown in Table 11 below;

[0195] Table 11

[0196] Experimental Group Number of bonding pads Bonding pad 1 Bonding pad 2 Example 1 1 (MP+CP)latex / Embodiment 17 2 MP Latex CP Latex

[0197] Test Example 3

[0198] Conjugate pad optimization

[0199] Test sample: immunochromatographic test paper provided in Examples 1, 13 to 17;

[0200] The positive quality control concentration used in this test example is 2 times the LOD of a single product. The test results are shown in Tables 12 to 14 below:

[0201] Table 12

[0202] Experimental Group T1 line reading (FluB) T2 line reading (FluA) T3 line reading (COV) Example 1 5 5 5 Example 13 5 4 4 Embodiment 14 5 4+ 5 Embodiment 15 4+ 4+ 4+

[0203] As shown in the table above, the experimental results of Examples 1 / 13 to 15 show that the chromatography distance will affect the detection sensitivity of the T line. The above experimental results show that the detection results of the new coronavirus antibody sprayed on the second conjugate pad are better.

[0204] Table 13

[0205] Experimental Group T1 Line Read (ADV) T2 line read (RSV) T3 Line Reading (HMPV) Example 1 5 5 5 Example 16 4+ 4+ 4+

[0206] As shown in the table above, the experimental results of Example 16 are slightly weaker than those of Example 1. Therefore, a double-layer conjugate pad is selected, that is, the first conjugate pad is coated with the first respiratory syncytial virus (RSV) antibody and the first adenovirus (ADV) antibody, and the second conjugate pad is coated with the first human metapneumovirus (HMPV) antibody.

[0207] Table 14

[0208] Experimental Group T1 Line Read (MP) T2 Line Read (CP) Example 1 5 5 Embodiment 17 5 5

[0209] As shown in the table above, there is no significant difference between the results of Example 1 and Example 17. Considering convenience and reducing labor costs, a mixed solution of latex microspheres labeled with MP+CP antibodies was selected.

[0210] Test Example 4

[0211] Detection sensitivity test

[0212] Test sample: the immunochromatographic test paper provided in Example 1;

[0213] Test method: The detection sensitivity of the immunochromatographic test strip provided by this invention was evaluated using recombinant proteins, and the minimum detection limit was: recombinant nucleocapsid protein of the new coronavirus: 10pg / Test; recombinant nucleocapsid protein of influenza B: 5ng / Test; recombinant nucleocapsid protein of influenza A: 100pg / Test; recombinant protein of adenovirus: 25ng / Test; recombinant protein of respiratory syncytial virus: 5ng / Test; recombinant protein of human metapneumovirus: 20ng / Test; recombinant protein of Mycoplasma pneumoniae: 100pg / Test; recombinant protein of Chlamydia pneumoniae: 20ng / Test.

[0214] (1) Verification of the sensitivity of COVID-19 detection.

[0215] The detection sensitivity of the recombinant protein of COVID-19 was verified by applying different concentrations of the pen and then performing chromatography. The experimental results are shown in Table 15, and the detection sensitivity of COVID-19 was determined to be 10pg / Test.

[0216] Table 15

[0217] Detection concentration T line reading 1pg / Test - 5pg / Test - 10pg / Test 3.5 40pg / Test 6 100pg / Test 8

[0218] (2) Verification of influenza B detection sensitivity.

[0219] Different concentrations of influenza B recombinant protein were selected and applied to the pen tip sampling head for chromatography. The results of the sensitivity verification of influenza B recombinant protein are shown in Table 16, and the detection sensitivity of influenza B was determined to be 5 ng / Test.

[0220] Table 16

[0221] Detection concentration T line reading 500pg / Test - 1ng / Test - 5ng / Test 3.5 10ng / Test 5 50ng / Test 8

[0222] (3) Validation of sensitivity of influenza A detection

[0223] Using influenza A recombinant protein, different concentrations were selected and coated on the pen tip sampling head and then chromatographed. The results of the sensitivity verification of influenza A recombinant protein are shown in Table 17, and the detection sensitivity of influenza A was determined to be 100 pg / Test.

[0224] Table 17

[0225] Detection concentration T line reading 1pg / Test - 10pg / Test - 100pg / Test 3.5 500pg / Test 5 2ng / Test 8

[0226] (4) Verification of adenovirus detection sensitivity

[0227] Using adenovirus natural antigen, different concentrations were selected and coated on the pen tip sampling head and then chromatographed. The results of the sensitivity verification of adenovirus natural antigen are shown in Table 18, and the detection sensitivity of adenovirus was determined to be 25 ng / Test.

[0228] Table 18

[0229] Detection concentration T line reading 1ng / Test - 10ng / Test - 25ng / Test 3.5 60ng / Test 5 300ng / Test 8

[0230] (5) Validation of sensitivity of respiratory syncytial virus detection

[0231] Using natural antigen of respiratory syncytial virus, different concentrations were selected and coated on the pen tip sampling head and then chromatographed. The sensitivity verification results of recombinant protein of respiratory syncytial virus are shown in Table 19, and the detection sensitivity of respiratory syncytial virus was determined to be 5ng / Test.

[0232] Table 19

[0233]

[0234]

[0235] (6) Validation of sensitivity of human metapneumovirus detection

[0236] Using human metapneumovirus recombinant antigen, different concentrations were selected and coated on the pen tip sampling head and then chromatographed. The results of the sensitivity verification of human metapneumovirus recombinant antigen are shown in Table 20, and the detection sensitivity of human metapneumovirus was determined to be 20ng / Test.

[0237] Table 20

[0238] Detection concentration T line reading 5ng / Test - 10ng / Test - 20ng / Test 3.5 40ng / Test 5 200ng / Test 8

[0239] (7) Verification of the sensitivity of Mycoplasma pneumoniae detection

[0240] Using the recombinant Mycoplasma pneumoniae antigen, different concentrations were selected and coated on the pen tip sampling head and then chromatographed. The results of the sensitivity verification of the recombinant Mycoplasma pneumoniae antigen are shown in Table 21, and the detection sensitivity of Mycoplasma pneumoniae was determined to be 100 pg / Test.

[0241] Table 21

[0242] Detection concentration T line reading 10pg / Test - 20pg / Test - 100pg / Test 3.5 200pg / Test 5 1ng / Test 8

[0243] (8) Detection sensitivity verification of Chlamydia pneumoniae

[0244] Using the recombinant Chlamydia pneumoniae antigen, different concentrations were selected and coated on the pen tip sampling head and then chromatographed. The sensitivity verification results of the recombinant Chlamydia pneumoniae antigen are shown in Table 22, and the detection sensitivity of Chlamydia pneumoniae was determined to be 20 ng / Test.

[0245] Table 22

[0246] Detection concentration T line reading 5ng / Test - 10ng / Test - 20ng / Test 3.5 40ng / Test 5 200ng / Test 8

[0247] Test Example 5

[0248] Actual sample testing

[0249] Virus detection experiment: The immunochromatographic test paper provided in Example 1 of the present invention was loaded into a pen-shaped housing to detect the viruses from Table 23. The test results are shown in Table 24:

[0250] Table 23

[0251] name source Species / Type Sample confirmation method Influenza B virus Guangzhou Clinical Influenza B Victoria strain PCR fluorescent probe Influenza A virus Guangzhou Clinical Influenza A (H1N1) PCR fluorescent probe SARS-CoV-2 virus Zhejiang Provincial Center for Disease Control and Prevention SARS-CoV-2 Fluorescence RT-PCR and sequencing Respiratory syncytial virus Zhejiang Provincial Center for Disease Control and Prevention RSV-A PCR fluorescent probe Adenovirus Zhejiang Provincial Center for Disease Control and Prevention Adenoviridae PCR fluorescent probe Human metapneumovirus Guangzhou Clinical A1 / B1 Fluorescence RT-PCR and sequencing Mycoplasma pneumoniae Guangzhou Clinical Mycoplasma Fluorescence RT-PCR and sequencing Chlamydia pneumoniae Guangzhou Clinical Chlamydia Fluorescence RT-PCR and sequencing

[0252] Table 24

[0253]

[0254]

[0255] As shown in the table above, the immunochromatographic test paper of the utility model can detect 7 to 8 common respiratory pathogens at the same time, and detect them at one time. The respiratory viruses include: new coronavirus, influenza A virus, influenza B virus, human metapneumovirus, respiratory syncytial virus, adenovirus, Mycoplasma pneumoniae, Chlamydia pneumoniae, and only one sample needs to be added. The operation is simple and cost-saving. This idea is used to detect antigens or antibodies of the same sample type. And the accuracy and precision of the immunochromatographic test paper are excellent. At the same time, the corresponding antibodies are labeled with latex microspheres to enhance the readability of the results.

[0256] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the utility model, rather than to limit it. Although the utility model has been described in detail with reference to the aforementioned embodiments, ordinary technicians in this field should understand that they can still modify the technical solutions recorded in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not make the essence of the corresponding technical solution deviate from the scope of the technical solution of the embodiments of the utility model.

Claims

1. An immunochromatographic test paper for detecting respiratory pathogens, characterized in that: The immunochromatographic test paper comprises a first test strip, a second test strip and a third test strip; The first test strip, the second test strip and the third test strip each independently include, along the chromatography direction of the sample to be tested: a sample pad, a binding pad, a detection pad and a water absorption pad sequentially arranged on the bottom plate; The conjugate pads are all coated with labeled antibodies labeled with markers; Among them, the labeled antibodies coated on the conjugate pad of the first test strip include a first new coronavirus antibody, a first influenza A virus antibody, and a first influenza B virus antibody; the labeled antibodies coated on the conjugate pad of the second test strip include a first respiratory syncytial virus antibody and a first adenovirus antibody; the labeled antibodies coated on the conjugate pad of the third test strip include a first Mycoplasma pneumoniae antibody and a first Chlamydia pneumoniae antibody; The detection pads are all coated with detection antibodies; Among them, the detection antibodies coated on the detection pad of the first test strip include a second new coronavirus antibody, a second influenza A virus antibody and a second influenza B virus antibody; the detection antibodies coated on the detection pad of the second test strip include a second respiratory syncytial virus antibody and a second adenovirus antibody; the detection antibodies coated on the detection pad of the third test strip include a second Mycoplasma pneumoniae antibody and a second Chlamydia pneumoniae antibody.

2. The immunochromatographic test paper for detecting respiratory pathogens according to claim 1, characterized in that: The labeled antibody coated on the binding pad of the second test strip also includes a first human metapneumovirus antibody; and the detection antibody coated on the detection pad of the second test strip also includes a second human metapneumovirus antibody.

3. The immunochromatographic test paper for detecting respiratory pathogens according to claim 1, characterized in that: The conjugate pad of the first test strip is composed of a single conjugate pad or 2 to 3 overlapping conjugate pads; The conjugate pad of the first test strip is composed of a single conjugate pad, and the labeled antibody coated on the conjugate pad is a combination of a first novel coronavirus antibody, a first influenza A virus antibody, and a first influenza B virus antibody; The conjugate pad of the first test strip includes: a second conjugate pad and a first conjugate pad along the chromatography direction of the sample to be tested; when the first conjugate pad is coated with the first influenza A virus antibody and the first influenza B virus antibody, the second conjugate pad is coated with the first novel coronavirus antibody; when the first conjugate pad is coated with the first novel coronavirus antibody, the second conjugate pad is coated with the first influenza A virus antibody and the first influenza B virus antibody; The conjugate pad of the first test strip includes: a third conjugate pad, a second conjugate pad and a first conjugate pad along the chromatography direction of the sample to be tested; the first conjugate pad is coated with a first influenza A virus antibody, the second conjugate pad is coated with a first influenza B virus antibody, and the third conjugate pad is coated with a first new coronavirus antibody.

4. The immunochromatographic test paper for detecting respiratory pathogens according to claim 1 or 2, characterized in that: The conjugate pad of the second test strip is composed of a single conjugate pad or two overlapping conjugate pads; The conjugate pad of the second test strip is composed of a single conjugate pad, and the labeled antibodies coated on the conjugate pad are the first respiratory syncytial virus antibody and the first adenovirus antibody; and / or, the labeled antibodies coated on the conjugate pad also include the first human metapneumovirus antibody; The conjugate pad of the second test strip includes: a second conjugate pad and a first conjugate pad along the chromatography direction of the sample to be tested; When the first conjugate pad is coated with a first respiratory syncytial virus antibody and a first adenovirus antibody, the second conjugate pad is coated with a first human metapneumovirus antibody; when the first conjugate pad is coated with a first human metapneumovirus antibody, the second conjugate pad is coated with a first respiratory syncytial virus antibody and a first adenovirus antibody.

5. The immunochromatographic test paper for detecting respiratory pathogens according to claim 1, characterized in that: The conjugate pad of the third test strip consists of a single conjugate pad; The labeled antibody coated on the conjugate pad of the third test strip is a combination of a first Mycoplasma pneumoniae antibody and a first Chlamydia pneumoniae antibody.

6. The immunochromatographic test paper for detecting respiratory pathogens according to claim 1, characterized in that: The detection pad of the first test strip includes: a detection line T3, a detection line T2, a detection line T1 and a quality control line C along the chromatography direction of the sample to be tested; Among them, the second new coronavirus antibody is coated in the area of ​​detection line T3, the second influenza A virus antibody is coated in the area of ​​detection line T2, and the second influenza B virus antibody is coated in the area of ​​detection line T1.

7. The immunochromatographic test paper for detecting respiratory pathogens according to claim 2, characterized in that: The detection pad of the second test strip includes: a detection line T2, a detection line T1 and a quality control line C along the chromatography direction of the sample to be tested; Wherein, the second adenovirus antibody is coated in the area of ​​the detection line T1, and the second respiratory syncytial virus antibody is coated in the area of ​​the detection line T2; Or, the detection pad of the second test strip includes: a detection line T3, a detection line T2, a detection line T1 and a quality control line C along the chromatography direction of the sample to be tested; Among them, the second human metapneumovirus antibody is coated in the detection line T3 area, the second respiratory syncytial virus antibody is coated in the detection line T2 area, and the second adenovirus antibody is coated in the detection line T1 area.

8. The immunochromatographic test paper for detecting respiratory pathogens according to claim 1, characterized in that: The detection pad of the third test strip includes: a detection line T2, a detection line T1 and a quality control line C along the chromatography direction of the sample to be tested; The second Chlamydia pneumoniae antibody is coated on the detection line T2 region, and the second Mycoplasma pneumoniae antibody is coated on the detection line T1 region.

9. A detection pen, characterized in that: The detection pen comprises the immunochromatographic test paper for detecting respiratory pathogens according to any one of claims 1 to 8 and a shell; the shell comprises a base and a pen body.

10. The detection pen according to claim 9, characterized in that: The base is filled with a sample lysis solution; The pen body is provided with a card slot for fixing the immunochromatographic test paper for detecting respiratory pathogens, and one end of the pen body close to the sample pad is provided with a sampling part in contact with the sample pad; the base is provided with a buckle for fixing the pen body; after the pen body is inserted into the base, the sampling part contacts the sample lysis solution, and the pen body is provided with a visual part for observing the detection pad.

Citation Information

Cited By

  • Respiratory tract eight-joint detection kit and preparation method thereof

    CN121049506A

  • Test strip for combined immunochromatographic detection of multiple respiratory pathogenic microorganisms

    WO2026113102A1